242 related articles for article (PubMed ID: 24754592)
1. Monoclonal antibodies as therapeutics in human malignancies.
Pandey M; Mahadevan D
Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic monoclonal antibodies in hemato-oncology].
Gennigens C; Collignon J; Jerusalem G; Rorive A; Sautois B
Rev Med Liege; 2009; 64(5-6):264-7. PubMed ID: 19642456
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody therapy for prostate cancer.
Jakobovits A
Handb Exp Pharmacol; 2008; (181):237-56. PubMed ID: 18071949
[TBL] [Abstract][Full Text] [Related]
4. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
5. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
6. The future of antibodies as cancer drugs.
Reichert JM; Dhimolea E
Drug Discov Today; 2012 Sep; 17(17-18):954-63. PubMed ID: 22561895
[TBL] [Abstract][Full Text] [Related]
7. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
8. Antibodies in oncology.
Pillay V; Gan HK; Scott AM
N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman RA
Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic monoclonal antibodies for hematological diseases].
Harada T; Abe M
Nihon Rinsho; 2014 Jun; 72(6):1143-8. PubMed ID: 25016818
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic human monoclonal antibodies against cancer.
Jarboe J; Gupta A; Saif MW
Methods Mol Biol; 2014; 1060():61-77. PubMed ID: 24037836
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
13. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
14. Future of monoclonal antibodies in the treatment of hematologic malignancies.
Reff ME; Hariharan K; Braslawsky G
Cancer Control; 2002; 9(2):152-66. PubMed ID: 11965235
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal antibody for cancer treatment].
Achiwa H; Sato S; Ueda R
Gan To Kagaku Ryoho; 2002 Apr; 29(4):495-501. PubMed ID: 11977531
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
Charmsaz S; Scott AM; Boyd AW
Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
[TBL] [Abstract][Full Text] [Related]
18. Antibodies and hematologic malignancies.
Smith MR
Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
[TBL] [Abstract][Full Text] [Related]
19. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic anti-VEGF antibodies.
Lien S; Lowman HB
Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
